Company intelligence / Profile preview

LanzaX

Skokie, Illinois, United Stateslanzatech.com ↗

Ownership: Private
Employees: ~30
Development stage: Commercial

Overview

LanzaX was formed as a spin-out joint venture from LanzaTech’s proprietary synthetic biology and strain engineering platform. The company inherits a robust pipeline of over 100 demonstrated molecules with existing synbio contracts. Its mission centers on accelerating project development in biochemicals, biomaterials, and specialty chemicals using engineered microbes. The move aims to fast-track commercialization while reducing costs by transferring more than 30 employees from the parent company.

Therapeutic areas: Other
Modalities: Engineered microbes/strains for biomanufacturingSynthetic biology platforms
Industry: Non-Drug Biotech

Partnerships

Tharsis Capital LLC

Beyond the preview

Go deeper on LanzaX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LanzaX.

Explore the full profile